A subject of debate, however, is whether the anti-CTLA-4 antibodies act in favor of anti-tumor immune responses or not, in terms of targeting the CTLA-4 molecules expressed on regulatory T-cells (Tregs). The gene discussed is CTLA4; the disease is neoplasm.